Results 181 to 190 of about 51,731 (234)

Evaluation of the anti-inflammatory potential of atorvastatin targeting TNF-α, IL-6, and IL-1β using integrated in vitro and in silico approaches. [PDF]

Sci Rep
Swaroop K, M R, Shaik S, Thatipelli RC, Krishna KVS, Ali Sangi SM, Islam MM, Meravanige G, Sreeharsha N, Chohan MS, Thapa S, Akin-Adewumi A, Atoki AV.   +12 more
europepmc   +1 more source

Diagnostic and Therapeutic Challenges in Statin-Induced Necrotizing Autoimmune Myopathy in an Elderly Patient: A Rare Case Report. [PDF]

Clin Case Rep
Shrestha N, Hassan A, Evans JA.
europepmc   +1 more source

Metabolic, enterohepatic and gut microbial effects of atorvastatin in healthy men. [PDF]

Endocr Connect
Thomasen M, Misiakou MA, Li SS, Rodriguez de Evgrafov MC, Lynggaard MB, Kårhus ML, Brønden A, Kornholt J, Chávez-Talavera O, Tailleux A, Staels B, Descat A, Hartmann B, Wewer Albrechtsen NJ, Rehfeld JF, Holst JJ, Vilsbøll T, Ellegaard AM, Sommer MOA, Sonne DP, Knop FK.   +20 more
europepmc   +1 more source

Synergistic effects of arsenic trioxide and atorvastatin on proliferation and apoptosis in acute lymphoblastic leukemia cells. [PDF]

Leuk Res Rep
Hassanpour Khodaei S, Sabetkam S, Mazloumi Z, Rafat A, Hekari D, Dizaji Asl K.   +5 more
europepmc   +1 more source

Toxic interaction between atorvastatin and clarithromycin causing myositis and rhabdomyolysis. [PDF]

Aust Prescr
Hurlbert M, Tay T, Holloway CJ, Girgis L.   +3 more
europepmc   +1 more source

Functional and Patient-Reported Outcomes in the Atorvastatin versus Placebo Trial of Hemorrhagic Cerebral Cavernous Malformations: An Exploratory Study.

Cerebrovasc Dis
Sader G, Alcazar-Felix RJ, Jhaveri A, Ali B, Stadnik A, Lee J, Shenkar R, Treine K, McBee N, Girard R, Thompson RE, Hanley DF, Awad I, Flemming KD.   +13 more
europepmc   +1 more source

Obicetrapib and ezetimibe enhance LDL receptor-mediated VLDL clearance and regress atherosclerosis on atorvastatin background. [PDF]

J Lipid Res
Inia JA, Zhang LH, Keijzer N, Worms N, van Nieuwkoop-van Straalen A, Ditmarsch M, de Kleer M, Jukema JW, Kastelein JJP, Szarek M, van den Hoek AM, Stokman G, Pieterman EJ, Princen HMG.   +13 more
europepmc   +1 more source

Comparative efficacy of lipid-lowering therapies on the cardio-renal-metabolic axis in diabetic kidney disease: a Bayesian network meta-analysis addressing residual CRM risk. [PDF]

Front Endocrinol (Lausanne)
Luo J, Dai Y, Wu C, Lan C, Shi J, Qi J, Hua S, An Y, Wang L, Li P, Liu P.   +10 more
europepmc   +1 more source

The lipid lowering efficacy of PCSK9 inhibitors alone vs. statins alone: a meta-analysis. [PDF]

Front Cardiovasc Med
Kyan K, Gornbein J, Saver J.
europepmc   +1 more source